April 20, 2021 -- Debiopharm has announced a global challenge in an effort to develop a single-dose messenger RNA (mRNA) COVID-19 vaccine.
Launched within the InnoCentive crowdsourcing innovation platform, the challenge seeks to identify a single-source mRNA vaccine that can provide the same level of COVID-19 protection as approved multidose vaccines, according to the company. The competition includes participants from various backgrounds, including science, engineering, and technology.
To participate, a written proposal must be submitted directly via the InnoCentive platform by the end of May. The winning proposal will be awarded a monetary prize and be acquired by Debiopharm for further development.
More information can be found on the challenge's website.